During acute myocardial infarction, phosphorylated TnI levels, Ca2+ sensitivity and ATPase activity are decreased in the myocardium, and the subsequent elevation in Ca2+ levels activates protease I (caplain I), leading to the proteolytic degradation of troponins. Concurrently, the levels of apelin and APJ expression are increased by limiting myocardial injury. In this prospective observational study, 100 consecutive patients with ST-elevation acute myocardial infarction were included. Patients meeting the following criteria were included in our study: (1) continuous chest pain lasting for >30 min, (2) observation of ST-segment elevation of more than 2 mm in two adjacent leads by electrocardiography (ECG), (3) increased cardiac troponin I levels, and (4) patients who underwent reperfusion therapy. We evaluated the levels of apelin-12 and troponin I on the first and seventh days after reperfusion therapy in all patients. Apelin-12 was inversely correlated with troponin I levels (Spearman’s correlation = −0.40) with a p value 2.2 for the association of apelin with MACE was determined, and the AUC was 0.71 (95% CI, 0.58–0.84). Survival analysis using the Kaplan-Meier method showed a lower rate of MACE among patients with apelin levels >2.2 (p = 0.002), and the ROC curve analysis showed a statistically significant difference in the area under the curve (p = 0.004). The influence of apelin levels on troponin levels in the acute phase of STEMI is inversely correlated, whereas in the non-acute phase, low apelin values were associated with a high rate of MACE.
1 January 2025 in Cardiology Research and Practice
Background: Increased level of high‐sensitivity C‐reactive protein (hs‐CRP) is associated with no‐reflow phenomenon. Therefore, even when timely coronary revascularization is performed through the primary percutaneous coronary intervention (pPCI), the process can induce reperfusion injury. Purpose: We evaluated the influence of hs‐CRP level on the no‐reflow phenomenon in patients with ST‐segment elevation myocardial infarction (STEMI). Methods: In this study, we included one hundred and eighty‐two consecutive patients with STEMI of onset < 12 h, who underwent pPCI. The levels of creatine kinase (CK), the MB fraction of creatine kinase (CK‐MB), troponin I, hs‐CRP, and other routine laboratory parameters were measured. Measurement of hs‐CRP was done on the day of admission by Cobas assay (particle‐enhanced immunoturbidimetric assay) on Cobas c501 (Roche). Thereafter, patients were divided in two groups according to the thrombolysis in myocardial infarction (TIMI) flow grade. Results: From a total of 182 STEMI patients who underwent pPCI, the median value of hs‐CRP of the patients with TIMI grade flow 3 (successful reperfusion) was 8.5 (0.4–268) and of the patients with no‐reflow phenomenon (unsuccessful reperfusion, TIMI flow grade ≤ 2) was 37.90 (1.8–271.20), p < 0.0001. Receiver operating characteristics (ROC) curve of hs‐CRP plots the true positive rate against the false positive rate at different cutoff points, AUC = 0.73 (95% CI, 0.64–0.81), and the cutoff value for the hs‐CRP was 18.0 mg/L, p = 0.0001. Conclusions: hs‐CRP may be associated with no‐reflow phenomenon in STEMI patients. The cutoff value for hs‐CRP may be used to identify patients at risk for reperfusion injury.
21 December 2023 in European Heart Journal - Case Reports
Background: A right single coronary artery (SCA) and hypoplastic coronary disease represent a rare coronary artery anomaly, which is associated with sudden cardiac death. The clinical manifestations of these anomalies depend on the distribution of collateral vessels. Case summary: A 55-year-old female presented with dyspnoea, mild chest pain during physical activity, and palpitations. Selective coronary angiography revealed a prominent SCA originating from the right coronary sinus. Approximately 2 mm from the ostium, this artery branched into two: a dominant right coronary artery (RCA) and a smaller artery for the anterior wall perfusion. The dominant RCA then moved posteriorly, bifurcating into a posterior descending artery and a posterolateral artery. The latter occupied the expected location of the left circumflex artery and supplied the majority of the coronary circulation, including the left ventricle. Notably, there were no significant atherosclerotic calcifications or stenoses observed. Discussion: We describe a unique case of a SCA that doesn’t conform to any category within the modified Lipton’s classification. Symptoms are speculated to arise from the compression of the SCA between the aorta and pulmonary artery during physical exertion. Additionally, hypoperfusion from the hypoplastic left coronary branch in the anterior wall warrants consideration. It’s paramount to meticulously evaluate the risk of sudden cardiac death when treating patients with a SCA. For high-risk patients, coronary artery bypass grafting should be contemplated. For our patient, given the clinical context, pharmacological treatment optimization was chosen.
Background: A decreased level of adiponectin is known as a predictor of adverse left ventricular remodeling and major adverse cardiac events (MACEs). We evaluated long-term MACEs following ST-segment elevation myocardial infarction (STEMI) in relation to adiponectin levels. Methods: This prospective study included a total of 73 consecutive STEMI patients. Adiponectin, CK, CK-MB, cTnI, CRP, HDL cholesterol, LDL cholesterol, triglycerides, and other routine laboratory parameters were considered, and myocardial revascularization and two-dimensional echocardiography were performed. Subjects were divided into two groups according to their serum adiponectin concentrations. Results: In total, 24 (32.87%) patients suffered from MACEs, 19 (26.02%) with adiponectin value ≤ 1.8 ng/mL (group 1) and 5 (6.84%) with adiponectin value > 1.8 ng/mL (group 2) (p < 0.013). Heart failure (Killip >1) was present in 14 cases (19.17%) in group 1 and in 3 cases (4.1%) in group 2 (p < 0.001). Kaplan–Meier analysis was used to depict the occurrence of MACEs according to the adiponectin threshold identified during hospitalization (1.8 ng/mL). The log-rank test revealed a statistically significant difference in survival between groups (p = 0.013), and the AUC value for adiponectin was 0.77 (95% CI, 0.66–0.89), p = 0.01. Based on univariate logistic regression analysis, adiponectin and BMI were significantly associated with MACEs (p = 0.018, p = 0.034). Multivariate logistic regression analysis shows that serum adiponectin predicts MACEs after STEMI (p = 0.011). Conclusions: We found significant associations between adiponectin levels and MACEs in patients who survived STEMI. The established cut-off value of 1.8 ng/mL for adiponectin during hospitalization identified patients at risk for MACEs.
Percutaneous patent foramen ovale (PFO) closure is an established therapy for secondary prevention of cryptogenic stroke. Device embolization is a rare but potentially serious complication, usually occurring early after implantation. A 68-year-old woman underwent PFO closure after ischemic stroke. At 3-month follow-up, the device was not visualized on transthoracic or transesophageal echocardiography. Computed tomography angiography revealed embolization to the distal abdominal aorta. The device was successfully retrieved using a percutaneous snare technique; retrieval was complicated by an infrarenal aortic dissection that was managed conservatively. Three weeks later, the patient experienced recurrent ischemic stroke and underwent repeat PFO closure with a larger device, without further complications. Percutaneous retrieval is a feasible first-line strategy in hemodynamically stable patients. Careful anatomical assessment and appropriate device sizing are essential to reduce the risk of embolization. This case highlights the importance of appropriate PFO occluder sizing in patients with PFO and atrial septum aneurysm to minimize the risk of device embolization. Although retrieval of a PFO occluder embolized into the aorta carries a risk of aortic wall injury, a percutaneous approach should be considered the first-line management strategy.
A major limitation of antegrade dissection and re-entry (ADR) is formation of an extraplaque hematoma that can hinder the crossing of coronary chronic total occlusions (CTOs). Use of the ReCross dual-lumen microcatheter (IMDS; Biotronik in the United States) can sometimes enable re-entry. Here we describe a patient with angina pectoris secondary to a CTO lesion in the right coronary artery and cardiac arrest resulting from ventricular fibrillation. An Astato XS 20 wire (Asahi Intecc Medical) was advanced through both exit ports of the ReCross microcatheter, followed by successful entry into the distal true lumen with a Pilot 200 wire (Abbott Vascular). Wiring the CTO through a ReCross dual-lumen microcatheter creates a smaller extraplaque hematoma and makes the ADR procedure easier. Other advantages are lower cost and more widespread availability. This case highlights the importance of multimodality intervention using the ReCross catheter in the treatment of complex coronary artery obstructive disease.